Cell Line
Engineering

Mammalian cell lines serve as the foundation of modern biopharmaceutical manufacturing, producing a wide range of therapeutic proteins, antibodies, vaccines, and gene therapy products. As biologics become increasingly complex, there is a growing need to improve cellular productivity, product quality, and manufacturing robustness while reducing development timelines and production costs. Advances in genome engineering, functional genomics, and systems biology have created unprecedented opportunities to understand and redesign cellular processes, enabling the development of next-generation production hosts optimized for industrial biomanufacturing.

Our research integrates cell line engineering, genome engineering, and functional genomics to improve the performance of mammalian production cells. Using technologies such as CRISPR-based gene editing, CRISPR activation (CRISPRa), CRISPR interference (CRISPRi), and high-throughput functional screening, we investigate the genetic and metabolic factors that govern cell growth, productivity, protein quality, and cellular stress responses. By combining genome-scale screening, systems-level analysis, and advanced bioprocessing approaches, we identify novel engineering targets and develop enhanced cell lines capable of supporting more efficient, reliable, and scalable biopharmaceutical manufacturing.